THE LANCET Infectious Diseases

Supplementary webappendix

Supplementary appendix

Safety and efficacy of retreatments with pyronaridine-artesunate in African malaria patients

Sagara, et al.

Table S1: **Dosing of pyronaridine-artesunate granule sachets and tablets and artemether-lumefantrine dispersible tablets and tablets was by body weight**

Drug	Body weight, kg	Dose and presentation
Pyronaridine-artesunate	5–<8	1 sachet
	8–<15	2 sachets
	15–<20	3 sachets
	20–<24	1 tablet
	24–<45	2 tablets
	45–<65	3 tablets
	≥65	4 tablets
Artemether-lumefantrine	5–<15	1 dispersible tablet
	15–<25 kg	2 dispersible tablets
	25–<35	3 tablets
	≥35	4 tablets

Table S2: **Adequate clinical and parasitological response (ACPR) at Day 28 and Day 42 in malaria patients treated with pyronaridine-artesunate or artemether-lumefantrine (episode 1, efficacy population; episodes 2–9, efficacy retreatment population)**

ACPR at:	Day 28		Day 42	
	Pyronaridine-artesunate (n=673)	**Artemether-lumefantrine (n=671)**	**Pyronaridine-artesunate (n=673)**	**Artemether-lumefantrine (n=671)**
Crude ACPR (intent-to-treat analysis)				
Episode 1	93·2 (620/665) [91·0–95·0]	80·4 (528/657) [77·1–83·3]	80·0 (532/665) [76·8–83·0]	65·9 (433/657) [62·1–69·5]
Episode 2	91·6 (197/215) [87·1–95·0]	80·3 (188/234) [74·7–85·2]	67·9 (146/215) [61·2–74·1]	60·7 (142/234) [54·1–67·0]
Episode 3	90·6 (58/64) [80·7–96·5]	82·1 (64/78) [71·7–89·8]	62·5 (40/64) [49·5–74·3]	62·8 (49/78) [51·1–73·5]
Episode 4	95·7 (22/23) [78·1–99·9]	73·7 (14/19) [48·8–90·9]	78·3 (18/23) [56·3–92·5]	63·2 (12/19) [38·4–83·7]
Episode 5	66·7 (2/3) [9·4–99·2]	100 (4/4) [39·8–100]	33·3 (1/3) [0·8–90·6]	50 (2/4) [6·8–93·2]
Episode 6–9*	100 (4/4)	100 (1/1) [2·5–100]	100 (4/4)	0 (0/1) [0–97·5]
Overall (GEE model)	92·7 [91·0–94·3]	80·4 [77·8–83·0]	77·3 [74·5–80·1]	65·4 [62·2–68·5]
Treatment difference	12·3 [9·1–15·4], *P* < 0.001		12·0 [7·7–16·2], *P* < 0.001	

PCR-adjusted ACPR (efficacy
evaluable analysis)

Episode 1	95·2 (628/660) [93·2–96·7]	96·4 (583/605) [94·5–97·7]	93·5 (565/604) [91·3–95·4]	95·7 (467/488) [93.5–97·3]
Episode 2	96·2 (205/213) [92·7–98·4]	98·1 (212/216) [95·3–99·5]	91·3 (167/183) [86·2–94·9]	94·1 (159/169) [89·4–97·1]
Episode 3	96·8 (61/63) [89·0–99·6]	95·8 (68/71) [88·1–99·1]	91·7 (44/48) [80·0–97·7]	91·5 (54/59) [81·3–97·2]
Episode 4	100 (23/23) [85·2–100]	94·1 (16/17) [71·3–99·9]	94·7 (18/19) [74·0–99·9]	92·3 (12/13) [64·0–99·8]
Episode 5	100 (3/3) [29·2–100]	100 (4/4) [39·8–100]	100 (2/2) [15·8–100]	100 (3/3) [29·2–100]
Episode 6–9*	100 (4/4)	100 (1/1) [2·5–100]	100 (4/4)	–

Data are ACPR % (n/N) [95%CI] except for overall (GEE model) which is % [95%CI].

*All four episodes 6–9 in the pyronaridine-artesunate group occurred in the same patient; all were treated successfully with pyronaridine-artesunate. One patient had a malaria episode 6 in the artemether-lumefantrine group which was a reinfection based on PCR results.

Table S3: **Kaplan-Meir estimates of parasite clearance time (PCT) in malaria patients treated with pyronaridine-artesunate or artemether-lumefantrine (episode 1, efficacy population; episodes 2–9, efficacy retreatment population)**

Episode	Pyronaridine-artesunate (n=673)		Artemether-lumefantrine (n=671)	
	Parasite clearance n/N	Median PCT (95%CI)	Parasite clearance n/N	Median PCT (95%CI)
1	645/665	24·8 (24·3–33·9)	648/658	34·5 (34·2–35·2)
2	213/214	24·1 (23·9–24·5)	232/233	24·2 (23·9–24·6)
3	64/64	23·9 (23·3–24·5)	76/77	24·5 (23·9–25·0)
4	23/23	24·1 (23·5–24·4)	19/19	24·1 (23·3–34·4)
5	3/3	24·6 (12·8–24·6)	4/4	24·6 (11·8–37·4)
6	1/1	11·9 (–)	1/1	25·5 (–)
7	1/1	23·5 (–)	–	–
8	1/1	34·4 (–)	–	–
9	1/1	21·1 (–)	–	–

Data are median (two-sided 95%CI).